InvestorsHub Logo
Followers 149
Posts 9211
Boards Moderated 5
Alias Born 03/29/2017

Re: None

Sunday, 02/11/2018 11:44:54 PM

Sunday, February 11, 2018 11:44:54 PM

Post# of 49532
Vital DD @ AMHD/HLK Biotec Holdings. Voting/control rights @ AMHD were transferred to TongRen Liu (who is tied to DOLV/JBZY) on November 25th 2017. TongRen/HLK purchased AMHD and brought it current and has cleared all debt/dilution off books. HLK is huge in China, as some of the bottom links show.

After Reverse Split, they will move assets/give new business plans. Ticker change will follow shorty after.

As of the date of this filing, November 25, 2017, TongRen Liu is the owner of 75,000,000 shares of Series A Preferred stock issued by the Company. For the reported period, Mr. Hirji was the owner of 75,000,000 shares of Series A Preferred stock issued by the Company. The transfer of the 75,000,000 shares of Series A Preferred stock issued by the Company occurred in late 2017.



HLK Biotec Holding Group, Inc officially purchased the Amelot holdings, Inc. (symbol: AMHD) on November 15, 2017 and became a publicly listing company in the OTC Markets. HLK Group Co., LTD. is the main health industry and engaged in research and development of high-tech health food, health care supplies, and low carbon environmental protection product for twenty years.



On November 25th and 26th they uploaded 22 filings to catch up current. Recent filings show NO DILUTIVE NOTES/WARRANTS tied 2 company. Only debt is a paltry 60k loan owed to officer with no dilutive terms attached.

Only problem with Shell was bloated Share count, which board voted and approved a Reverse Split with a ratio of 1:1000. They also voted to lower Authorized Share count to 500,000,000.

Total shares authorized: 5,000,000,000 as of: September 30, 2017
Total shares outstanding: 4,624,573,155 as of: September 30, 2017


After RS

Total shares authorized: 500,000,000
Total shares outstanding: 4,624,573


On December 1, 2017, the Company's Board of Directors voted and approved to change the Company's name to HLK Biotec Holding Group, Inc., reverse split the Company's common stock on a 1:1000 ratio and change the authorized Common stock to 500 million shares. The proposed corporate actions were approved by shareholder(s) holding seventy percent (70%) of the shareholder vote.

On December 4, 2017, the Company filed an Amendment to its Articles of Incorporation to effectively complete all three actions approved by the Board, and filed an Issuer Company Related Action Notification form with the Financial Industry Regulatory Authority



https://www.otcmarkets.com/stock/AMHD/disclosure

https://backend.otcmarkets.com/otcapi/company/financial-report/183996/content

http://www.hk-hlk.com/en/newsview1.htm

http://www.hk-hlk.com/en/about.htm

https://wyobiz.wy.gov/Business/FilingDetails.aspx?eFNum=097129132140139240204165015028199220224008001166

http://m.jiaju.qincai.net/corp-438393.html

http://m.58food.com/index.php?moduleid=4&username=hlk999

New CUSIP number which shows Name Change coming.